Skip to main content
. Author manuscript; available in PMC: 2019 Aug 16.
Published in final edited form as: Cell Rep. 2019 Jun 25;27(13):3741–3751.e4. doi: 10.1016/j.celrep.2019.05.101

Figure 5. Chronic Levetiracetam Treatment Improves Spatial Discrimination in APP Mice.

Figure 5.

(A) Spatial discrimination task. Mice were trained with two identical objects placed on one side of cage, then tested with one object displaced to one of four positions (P1–P4).

(B) Percentage of time spent with the displaced object (DO) in 3–3.5-month-old NTG (top) and APP (bottom) mice at each of the four positions (P1, P2, P3, P4) during training and test trials (n = 6–8 mice per genotype and position, total 57 mice). NTG mice (top), two-way ANOVA: test phase (p < 0.0001), position and test phase interaction (p < 0.001). APP mice (bottom), two-way ANOVA: test position (p < 0.01), phase (p < 0.001), position and test phase interaction (p < 0.001).

(C) Percentage of time spent with the DO at P2 in 3-month-old NTG and APP mice after 4 weeks of treatment with saline or levetiracetam (n = 6–8 per genotype/treatment, total 30 mice). Two-way ANOVA: treatment (p < 0.001), test phase (p < 0.0001), treatment and test phase interaction (p < 0.001).

*p < 0.05; **p < 0.01; ***p < 0.001; Holm-Sidak post hoc test. Values indicate mean ± SEM. See also Figures S7 and S9 and Table S2.